Press Releases

11 Jul '22
TScan screening technology used to identify the targets of expanded T cell clones in the tumors of patients with head and neck cancer responding to neoadjuvant immunotherapy TCR for C*07:02-restricted epitope on MAGE-A1 forms the basis of TScan’s TSC-204-C07 TCR-T therapeutic candidate for the...
Additional Formats
07 Jul '22
WALTHAM, Mass., July 07, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of...
Additional Formats
Displaying 1 - 10 of 18